Introduction
============

Tuberculosis remains a leading cause of death worldwide which afflicts approximately one-third of the world\'s population and claims a death toll around 1.2 million annually [@B1].

*Myc*obacterium tuberculosis (*Mtb*) is an unusual facultative intracellular pathogen which multiplies within macrophage [@B2]. Macrophages are crucial for the innate and adaptive immune response to *Mtb* because of their potent antimicrobicidal activities, antigens-presenting abilities, secretion of inflammatory mediators such as the IL-12 family of cytokines [@B3], [@B4], and their role in granuloma formation to control the pathogen [@B5]-[@B7]. However, *Mtb* can persist within granuloma lifelong without clinical symptoms [@B3], [@B4], [@B8]. In-depth understanding of the underlying molecular mechanisms can inspire better drug design and treatment of TB.

The interleukin-12 (IL-12) family, including IL-12, IL-23, IL-27 and IL-35, are important for TB pathogenesis and control, which can regulate the Th1 response [@B9], [@B10].

Interleukin-27 (IL27) was first discovered in 2002 as a new member of the IL-12 cytokine family [@B11]. It is a heterodimer, comprised of p28 and EBI3 subunits that are structurally similar to the p35 and p40 subunits of IL-12 [@B12].

IL-27 is largely secreted from activated antigen-presenting cells (APCs) such as macrophages and Dendritic cells (DCs) [@B13]-[@B15] (Figure [1](#F1){ref-type="fig"}). The receptor of IL-27 consists of two subunits: IL-27Rα and gp130. Both subunits are essential [@B16]-[@B18] for activating Janus Kinase (Jak) and Transcription factor (Stat). Specifically, Stat1and Stat 3 are predominant mediators of IL-27 effects (figure [2](#F2){ref-type="fig"}) [@B19], [@B20]. IL-27 can mediate Th1 cells differentiation and proliferation [@B17], [@B18]. IL-27 has potent antitumor activities by activation of cytotoxic T lymphocytes CD8+ T cells [@B21]-[@B25], Natural killer (NK) cells [@B26]-[@B28], NK T cells [@B28] and anti-angiogenic factors [@B29], [@B30]. However, IL-27R signaling was demonstrated to be involved in the potent antagonizing of Th1, Th2 and Th17 inflammatory responses [@B31]-[@B33] and agonist of Tr1 cell response [@B34], [@B35]. IL-27 can ameliorate symptoms of autoimmune diseases in preclinical studies [@B33], [@B36], [@B37].

The expression level of IL-27 in granuloma suggested a role in tuberculosis [@B38]. The elevated level of IL-27 in tuberculous pleural fluid suggested a potential biomarker for tuberculous pleurisy diagnosis [@B39], [@B40]. IL-27 level might be manipulated to benefit pathogen [@B41]-[@B43].

Molecular characteristics of IL-27
==================================

IL27 is a heterodimeric cytokine consisting of p28 and Epstein-Barr virus induced gene 3 (EBI3) subunits [@B16], [@B44]. EBI3 expression is high in human B lymphoblast cell lines transformed *in vitro* by EBV, activated APCs and placental syncytiotrophoblasts [@B16], [@B45]. EBI3 is a 34-kDa glycoprotein similar to the p40 subunits of IL-12 [@B46]*.* The EBI3 reversibly binds to IL-12p35-related subunit, namely p28, to form heterodimeric cytokine IL-27[@B46], [@B47]. The connection between p28 and EBI3 is labile and these subunits can be secreted independently [@B16]. EBI3 is also capable of binding to the IL-12p35 to form IL-35 [@B48]. The human p28 gene encodes a 24.5kDa polypeptide [@B16]. The p28 is structurally similar to an IL-6/IL-12 family, composed of a long chain of four α helix bundle named A-D from the N terminus to the C terminus[@B49]. The polypeptide loop connecting the p28 C and D α helices contains a stretch of polyglutamic acids (poly-E) unique among helical cytokines and is highly conserved [@B50]. The p28 alone can suppress IL-27 mediated Th1 responses [@B51] and IL-6 mediated signaling [@B52]. These data suggest a regulatory role of p28 in IL-27-mediated immune response.

A polymorphism (-964A\>G) in the p28 promoter has been noted in certain diseases such as asthma [@B53], inflammatory bowel diseases [@B54], chronic obstructive pulmonary disease[@B55], and epithelial ovarian cancer [@B56], which seems to be associated with an increase in disease susceptibility. However, the effects of SNPs on the expression of IL-27 remain elusive.

IL-27 is mainly produced by activating APCs such as DCs and macrophages (figure [1](#F1){ref-type="fig"}). Macrophages-stimulated with TLRs agonists, (polyinosinic: polycytidylic acid (poly (I:C)), Lipopolysaccharide (LPS), or R848 can induce both subunits of IL-27 [@B13]. It has been reported that p28 production is completely dependent on the TLR4-associated myeloid differentiation factor 88 (MyD88) mediated pathway and partially dependent on NF-κBc-Rel transcription factor [@B14]. MyD88 also regulates p28 expression through binding of AP-1/c-Fos to the p28 promoter in both human and mouse macrophages. However, the binding of c-Fos to the p28 promoter can be blocked by overexpression of p38 MAPK [@B57]. In addition, TLR4 can induce the expression of p28 subunit through activating the TIR domain-containing adaptor inducing IFN-β (TRIF) and IFN regulatory factor 3 (IRF3) pathways [@B58]. TLR2, TLR4, and TLR9-associated MyD88 are required for the induction of EBI3 expression through binding of NF-kB subunits (p50/p65) and PU.1 to the EBI3 promoter [@B59].

IFN-alpha can promote the production of IL-27 by enhancing the expression and binding of IRF-1 to the IFN-stimulated response element (ISRE) in the p28 gene promoter [@B13]. Likewise, IFN-γ induced IRF-8 expressions can upregulate p28 gene transcription in synergy with IRF-1 [@B15]. IFN-γ can selectively induce IL-27 expression via activating the C-Jun N-terminal kinases (JNK), MAPKs and the phosphoinositide-3-kinase (PI3K) signaling in primary human monocyte[@B60]. Many molecular details of the negative regulation of IL-27 expression remain to be determined.

IL-27 signaling pathways
========================

IL-27R is indispensable for the IL-27 signaling. IL-27R consists of the class I cytokine receptor family (TCCR) (also known as WSX-1) and gp130 [@B16]-[@B18]. IL-27R is expressed in various cell types including naïve T cells, NK cells, activated B cells, monocytes, dendritic cells, activated endothelial cells, and mast cells [@B61]. IL-27 induced intracellular signaling involves phosphorylation of different isoforms of Jak and Stat, which varies with immune cell types: Jak1, Jak2, Tyrosine kinase 2 (Tyk2), Stat1, 2, 3, 4 and Stat5 in naïve CD4 T cells [@B62], Jak-1, Stat1, Stat-3 and Stat5 in NK cells[@B61], [@B63] , Stat1, Stat3, and NF-κB activation in monocytes [@B20], and Stat-3 in mast cells [@B64]. Interestingly, the effect of the IL-27 can be both pro-inflammatory and anti-inflammatory via same Stat1/Stat3 signaling.

The pro-inflammatory role of IL-27 as key inflammatory mediator for Th1 differentiation and IFN-γ production has been intensively explored [@B16], [@B63], [@B65]. Stimulation of Th0 in the presence of IL-27 induces the expression of the key signature Th1 cytokine IFN-γ via up-regulating of the transcription factor T-bet and IL-12Rβ2 chain which is essential for responding to IL-12 and the differentiation of a Th1 phenotype [@B61], [@B62], [@B65]. This effect of IL-27 on Th cell depends on multiple transcription factors such as Stat-1 and Stat-3 [@B61], [@B62], [@B65]. *In vivo* studies demonstrated the role of IL-27 in Th1 responses. In this context, it was shown that WSX-1-/- mice were more susceptible to *Leishmania major* infection and impaired IFN-γ production [@B17]. Similarly, reduced Th1 responses and IgG2a production was demonstrated in WSX-1-deficient mice infected with *Listeria monocytogenes*[@B18]. Moreover, it was shown that IL-27R signaling is vital *in vivo* for the IFN-γ production by CD8+ T cells [@B66]. IL-27 can enhance the proliferation of naïve CD8+ T cells and IFN-γ and granzyme B production dependent on Stat1 and Stat3 [@B22].

IL-27 can stimulate human monocyte to express TLR4 through activation of Stat-3, and NF-κB which subsequently respond to LPS-inducing IL-6, TNF-α, MIP-1α, and MIP-1β expression [@B67]. IL-27 increased the production of nitric oxide from peritoneal macrophages via activation of Stat-1, NF-κB and MAPKs [@B68]. IL-27 also enhanced monocyte derived dendritic cells (moDCs) to express IL-27, IL-8, CXCL10, chemokine receptor (CCR1), IFN-stimulated genes, IRF8 and other genes involved in antigen presentation [@B69]. IL-27 negatively regulated Tr1 cells by induction of metallothioneins (MTs) which in turn reduced stat1 and stat3 phosphorylation resulting in impaired IL-10 production [@B70]. Taken together, IL-27 positively regulates both innate and adaptive immune responses.

IL-27 can negatively modulate inflammatory processes. Improved control of *Leishmania donovani* correlates with massive inflammatory responses were reported in IL-27R-deficient mice [@B71]. Similarly, WSX-1-/- mice infected with *Toxoplasma gondii* or *Trypanosoma cruzi* generated robust IFN-γ responses and developed lethal T cell-mediated inflammation [@B31], [@B72]. Greater effector and memory CD4+ T cells responses were noted in IL27R lacking mice challenged by *Plasmodium berghei* [@B73].

The negative feedback of IL-27 largely depends on the induction of type 1 regulatory T cells (Tr1). IL-27 can induce Tr1 cells via various mechanisms including activation of Stat1, Stat3 [@B75]-[@B76], upregulation of Blimp1 [@B77], aryl hydrocarbon receptor (AhR), transcription factor c-Maf, inducible T cell costimulator (ICOS), and IL-21 production, which is indispensable for the expansion and maintenance of Tr1 cells [@B34], [@B35]. Furthermore, the anti-inflammatory effect of IL-27 needs more than the induction of Tr1 cells. IL-27R-/- CD4+ T cells produce more IL-2 than wild-type during *in vitro*differentiation. The addition of recombinant IL-27 suppressed the expression of IL-2 both transcriptionally and translationally [@B78]. IL-27 suppresses CD28-mediated IL-2 production by Stat 1 which in turn induces the expression of the suppressor of cytokine signaling 3 (SOCS3) [@B79]. Moreover, it was observed that WSX-1-deficient macrophages are more efficient in inducing IFN-γ and IL-17A production by CD4+ T cells than control. IL-27 can activate stat1 which in turn suppresses cyclooxygenase (COX) expression and followed by reducing prostaglandin (PG2) secretion, which can affect the CD4+ T cell responses [@B80].

IL-27 was also reported to suppress Th2 cells development and their cytokines production by downregulation of Gata3 and upregulation of T-beta in differentiated Th2 cells [@B32]. In addition to suppress both Th1 and Th2 cells, IL-27 can inhibit the development of Th17 cells. Consistently, it was demonstrated that IL-27 can inhibit Th17 cell development through various mechanisms including the suppression of IL-6 signaling mediated IL-17 production [@B33], retinoid-related orphan receptor γ (RORγ) expression (Th17-specific transcription factor) [@B36], and also via induction of the IL-10 production [@B81], and programmed death ligand 1 (PD-L1) on naïve T cells [@B37]. IL-27 upregulates the expression of Blimp1 in pre-committed Th17 cells and acquired a Tr-1-like phenotype characterized by the production of IL-10 and IFN-γ [@B77].

More recently, it was recognized that IL-27 can inhibit the development of Th9 cells and limit its related encephalitis by mechanism partly depending on Stat-1 [@B82]. Taken together, IL-27 induces an immunosuppressive effect by both Tr1 cells dependent and independent mechanisms. However, the contribution of IL-27 in the induction of IL-35-producing T regulatory cells remains unknown.

Role of the IL-27 in innate and adaptive immune response to *Mtb*infection
==========================================================================

The innate immunity plays a decisive role in the early clearance of *Mtb* via the recognition of the antigen and subsequent induction of pro-inflammatory cytokines and antimicrobial peptides [@B83]. The production of IL-27 in response to *Mtb* infection modulates macrophage responses [@B41]-[@B43]. The combination of IL-12 and anti-IL-27R can limit *Mtb* growth via upregulation of pro-inflammatory cytokines such as TNF-α, IFN-γ, and IL-18[@B41], [@B84]. However, the molecular mechanisms by which IL-27 negatively regulated macrophages during *Mtb* infections remain unclear. It was demonstrated that IL-27R singling in mice peritoneal macrophages suppresses IL-12 and TNF-α production by Stat3 [@B43]. IL-27 can antagonize IL-18 signaling in human macrophages challenged with *Mtb* by inhibiting the expression of the IL-18 receptor beta-chain and IL-18R downstream signaling component NF-kB [@B42]. IL-18 and IL-12, synergistically induced IFN-γ production by human macrophages and promoted the killing of *Mtb* [@B84]. It has been shown that IL-27 can inhibit the expression of the phagosomal vacuolar ATPase (V-ATPase) and lysosomal integrated membrane protein-1 (CD63), resulted in the suppression of phagosomal acidification and cathepsin D maturation [@B85]. IL-27 signaling is necessary for the IL-10 production by macrophages through enhancing the activity and binding of Stat1/Stat3 to the IL-10 promoter [@B86]. Recently, it was found that IL-10 induced by *Mtb*during macrophage infection can manipulate phagosomal maturation to enhance its own intracellular growth [@B87]. Most recently a study demonstrated that IL-27 suppresses IFN-γ mediated autophagy in human macrophages infected with *Mtb* by inducing autophagy negative regulatory factors mTOR and Mcl-1 through JAK/PI3-K/Akt and PI3-K pathway, respectively [@B88]. In brief, *Mtb* can subvert the normal bactericidal function of macrophages by inducing IL-27 (Figure [2](#F2){ref-type="fig"}A, Table [1](#T1){ref-type="table"}).

Ablation of IL-27, either by disruption of the IL-27R gene in mice or by an antibody blockade of the IL-27R, implicates an important role of IL-27 in adaptive immunity against mycobacteria infections. WSX-1-deficient mice have impaired IFN-γ production and granuloma formation when challenged with *M. bovis* BCG [@B89]. However, there are no differences in liver pathology and bacterial load between mutant and wild type mice [@B89]. Significant elevation of IL-27 throughout the infanthood and neutralization of IL-27 in neonatal macrophages improved control of bacterial replication [@B90]. Furthermore, blockade of IL-27 during incubation with the *M. bovis* (BCG) augmented the IFN-γ production by allogeneic CD4+ T cells [@B90]. Similarly, it has been demonstrated that improved control of *Mtb* growth in the lungs results from increased production of pro-inflammatory cytokines in WSX-1-knockout mice [@B43]. These results suggest that IL-27 negatively regulated Th1 response (Figure [2](#F2){ref-type="fig"}B, Table [1](#T1){ref-type="table"}), however, the underlying mechanisms remain elusive.

More recently, it was recognized that IL-27 positively regulates IL-10 producing Tr1 cells during chronic inflammation [@B34], [@B35], [@B75]-[@B77] (Figure [2](#F2){ref-type="fig"}B, Table [1](#T1){ref-type="table"}). It has been demonstrated that IL-10 suppressed the immune response to *Mtb* infections without immunopathology observed in both C57BL/6 and CBA/J mice [@B91], [@B92]. Moreover, it was shown that IL-10-deficient mice were more resistant to *M. bovis*(BCG) challenge in comparison to control mice [@B93]. Blocking of IL-10R in CBA/J mice improved *M. bovis*(BCG) evoked protection against *Mtb* characterized by enhanced Th1 and Th17 responses and increased IFN-γ and IL-17A production in the mice lungs [@B94]. Taken together, these data indicate IL-27 can modulate immune response against mycobacteria by inducing IL-10.

IL-27 directly mediated the suppression of the development of Th17 cells in chronic inflammation models [@B33], [@B36], [@B37], [@B81] (Figure [2](#F2){ref-type="fig"}). Th7 cells induce T cell chemokines (CXCL9, CXCL10 and CXCL11) in the lungs of infected mice to recruit IFN-γ-producing CD4+ T cells to limit *Mtb*growth [@B95]. BCG-induced Th17 cells which can downregulate IL-10 and generate Th1 immune response resulted in protection upon *Mtb*challenge [@B96]. IL-17-deficient mice were more susceptible to mycobacteria, evidenced by the impaired granulomas formation and decreased IFN-γ production [@B97]. Vaccination will elicit Th17 cells response associated with increased pro-inflammatory cytokines, granulocytes infiltration and severe lung damage in mice [@B98]. The higher amount of Th17 cells and related cytokines in active tuberculosis patients implicated a role in immunopathogenesis [@B99], [@B100].

As an exceptional successful silent killer, *Mtb*can manipulate the host signaling to persist and reactivate at opportune occasion. Knowledge about the emerging player, namely IL-27, will inform better countermeasures against this hideous threat of global health public.
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![**Signaling involved in IL-27 expression.**IL-27 is largely produced by Antigen-presenting cells (APCs) such as Dendritic cells (DCs) and macrophages upon stimulation with TLRs agonists, IFN-α, IFN-γ or microbial infections. It consists of two subunits (p28/EBI3) which are expressed independently. TLR2, TLR4 and TLR9-associated MyD88 can induce EBI3 expression through the binding of NF-𝛋B subunits (p50/p65) and PU.1 to the EBI3 promoter. TLR4-associated MyD88 induces p28 expression through binding of NF-𝛋B-c-Rel and AP-1/c-Fos to the p28 promoter, TLR4-associated TRIF induces p28 expression by binding of IRF3 to the p28 promoter. The IFN-α and IFN-γ induces p28 expression through the binding of IRF3 and IRF8 to the p28 promoter, respectively. In addition, IFN-γ-mediated IL-27 instead of IL-27p28 gene expression is positively regulated by the C-Jun N-terminal kinases (JNK), mitogen-activated protein kinases (MAPKs) and the phosphoinositide 3-kinase (PI3K).](ijbsv11p0168g001){#F1}

###### 

**Regulatory role of IL-27 in the immune response against Mycobacterium tuberculosis. (A)** IL-27 induced by *Mtb* infection modulates macrophage response. IL-27 inhibits autophagy by inducing negative regulator factors of autophagy mTOR and Mcl-1 through PI3K/AKT and PI3K, respectively. IL-27 induces IL-10 production through Stat1/Stat3, which in turn blocks phagosomal maturation. It also suppresses TNF-α and IL-12 via Stat3 and both cytokines required for augmenting IFN-γ production by macrophages. In addition, IL-27 targeting NF-kB to inhibit IL-18 mediated IFN-γ production. Suppression of IFN-γ led to down-regulation of V-ATPase and CD63 and Capethsin D (CD) and subsequently suppression of phagosomal acidification. (B) IL-27 induced IL-10-producing type 1 regulatory T cells (Tr1) cell via Stat1/Stat3 and AhR/c-Maf pathway, which in turn suppress Th1 and Th17 cells. IL-27 directly inhibits Th17 cells by inhibiting ROR-γ expression and IL-6 signaling.
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###### 

The consequence of IL-27 signaling in tuberculosis

  Immune cells involved                                                                         Consequence of IL-27 signaling                          References
  --------------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------
  Macrophages                                                                                   Inhibits the production of pro-inflammatory cytokines   [@B43]-[@B42]
  Induces the production of anti-inflammatory cytokine.                                         [@B86]                                                  
  Inhibits phagosomal acidification.                                                            [@B85], [@B87]                                          
  Suppresses the autophagy formation.                                                           [@B88]                                                  
  T cells                                                                                       Suppresses Th1 cell responses.                          [@B43], [@B89]-[@B90].
  Induces the IL-10 producing Tr1 cells, promotes proliferation and maintenance of Tr1 cells.   [@B34]-[@B35], [@B75]-[@B77], [@B94].                   
  Suppresses the Th17 cell development.                                                         [@B33], [@B36], [@B37], [@B81].                         
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